A blinded randomized study comparing intubating conditions after either rocuronium 0.6 mg·kg<sup>−1</sup> or remifentanil 2 µg·kg<sup>−1</sup> in elderly patients
Matias Vested, Anne Marie Sørensen, Cecilie Bjerring, Rasmus Ejlersgaard Christensen, Felicia Dinesen, Malene Vang, Alexander Gilvanoff, Thea Ellehammer Hansen, Tatiana Nielsen, Lars S. Rasmussen
Abstract
Abstract Background To facilitate tracheal intubation, either a neuromuscular blocking agent or a bolus dose of remifentanil can be administered. We hypothesized that rocuronium 0.6 mg·kg −1 provided a larger proportion of excellent intubating conditions compared to remifentanil 2 µg·kg −1 in patients above 80 years. Methods A total of 78 patients were randomized to either rocuronium 0.6 mg·kg −1 or remifentanil 2 µg·kg −1 . General anaesthesia was initiated with fentanyl and propofol. Two minutes after the administration of either rocuronium or remifentanil, tracheal intubating conditions were evaluated using the Fuchs‐Buder scale by a blinded investigator, and our primary outcome was the proportion of patients presenting intubating conditions deemed as excellent. Further outcomes included the Intubating Difficulty Scale (IDS), hoarseness or sore throat 24 h postoperatively, and intervention against hypotension. Results No difference in the occurrence of excellent intubating conditions was found comparing the rocuronium group with the remifentanil group; 10 (28%) versus 15 (39%) ( p = .29), respectively, relative risk = 0.72. Interventions against hypotension were used in 24 (67%) versus 28 (74%) ( p = .51), respectively. Hoarseness and sore throat 24 h postoperatively were found in 37% versus 35% p = .86, and 14% versus 5% p = .20, respectively. The IDS score was 2 versus 2 p = .48. Conclusion No difference in intubating conditions was found 2 min after the administration of either rocuronium 0.6 mg·kg −1 or remifentanil 2 µg·kg −1 in patients aged above 80 years. Intubation conditions were less than optimal in a large proportion of this patient population. Clinical trials registration NCT04287426.